Clinical Trial Update: E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating E7050 plus sorafenib versus sorafenib alone as first-line therapy in hepatocellular carcinoma has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• E7050
• Sorafenib (Sorafenib)

Snippet

Sponsor: Eisai Inc. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-08